The Korea Investor Relations Service (KIRS) Corporate Research Centre published an initiation report on 19 August covering Olix Pharmaceuticals (KOSDAQ: 226950), a gene-silencing biotech, forecasting revenues of 43.9bn won in 2026 — a 199.3% increase on the prior year.

Olix has built its business around a proprietary RNA interference (RNAi) platform called OASIS, which is based on its asymmetric small interfering RNA (siRNA) technology. The company combines this with tissue-specific delivery systems targeting the liver, skin, and eye, and has signed technology-transfer and co-development agreements with Eli Lilly of the United States, L'Oréal of France, and Chinese pharmaceutical firm Hanso Pharma.

From single pipeline to platform company

The central thesis of the KIRS report is that Olix is graduating from an early-stage biotech built around a single asset into a genuine platform company spanning multiple tissue types and metabolic pathways. The inflection point was a technology-transfer agreement signed with Eli Lilly in February 2025. Under that deal, Olix licensed OLX702A — a candidate therapy for metabolic dysfunction-associated steatohepatitis (MASH, a severe form of fatty liver disease) and obesity — to Lilly for up to $630m (approximately 912bn won). Under the contract structure, Olix will complete a Phase 1 trial in Australia, after which Lilly assumes responsibility for further development and commercialisation.

Interim Phase 1 results for OLX702A are striking: a single injection produced an average reduction in liver fat of 60–80%, with a peak of approximately 90%, and some patients maintained the effect for over ten months. The final patient visit was completed in May 2026, and the consolidated clinical study report (CSR) is expected in the second half of 2026. The KIRS report is careful to note that the data published so far do not include placebo-adjusted outcomes or a full tolerability analysis. It also cautions that resolution of MASH or improvement in liver fibrosis has not yet been demonstrated in humans, and that the current results should be interpreted only as early clinical signals.

The key near-term catalyst is how quickly Lilly moves into Phase 2 after Phase 1 concludes. The agreement also gives Lilly right of first refusal should Olix develop a dual-siRNA candidate targeting both MARC1 and another gene simultaneously, leaving open the possibility of a broader commercial relationship.

The next obesity candidate

Olix's second obesity candidate, OLX501A, is also drawing attention. It works by suppressing ALK7 messenger RNA in fat cells, thereby activating lipolysis. Crucially, its mechanism of action differs from GLP-1 receptor agonists — the dominant class of weight-loss drugs — suggesting potential for combination use. Data presented at the company's R&D Day in July 2026 showed that, in obese primates, ALK7 mRNA was suppressed by approximately 89% at day 70, and visceral fat volume fell 29.2% from baseline by day 49. Olix says its results compared favourably to those of a rival compound from Arrowhead Pharmaceuticals targeting the same pathway. The company aims to file an Investigational New Drug (IND) application for OLX501A in the first half of 2027.

L'Oréal deepens its commitment

The relationship with L'Oréal has also moved well beyond a preliminary collaboration. What began as a joint research agreement on skin and hair regeneration in June 2025 has since advanced rapidly: Olix hit a milestone and received a royalty payment in December 2025; L'Oréal's venture fund BOLD participated in a third-party rights offering of approximately 10.5bn won in June 2026; and that same month the two companies signed a Pipeline Collaboration Framework Agreement extending co-development to skin, hair, and nail health. Within roughly a year, the partnership has progressed through joint research, milestone achievement, strategic equity investment, and multi-pipeline collaboration.

Fundraising shores up the balance sheet

In June 2026, Olix completed a rights offering totalling approximately 110.7bn won, placing shares with both BOLD and US asset manager Weiss Asset Management. The proceeds are earmarked for the Phase 1 trial of OLX104C and for advancing Olix's OASIS-Adipose, OASIS-CNS, and Dual-siRNA platform programmes.

Financials: revenues rising, losses persistent

In 2025, revenues rose 158.3% year-on-year to 14.7bn won, but operating losses remained around 30bn won. A non-cash gain of approximately 21.6bn won from the revaluation of convertible bond derivatives helped reduce the net loss attributable to shareholders from 40.7bn won in 2024 to 15.7bn won in 2025 — an accounting effect rather than an operational improvement.

The 2026 revenue forecast of 43.9bn won rests primarily on the assumption that a development milestone of approximately $20m will be recognised in the second half of the year, triggered by Lilly advancing OLX702A into Phase 2. Because the milestone conditions and amounts are confidential under the contract, the timing and scale of recognition could vary considerably. The report acknowledges this uncertainty and notes that it has conservatively excluded any new technology-transfer deals from its estimates.

Risks investors should weigh

The risks are not insignificant. Commercial precedents for siRNA therapies in MASH, alopecia, and macular degeneration — Olix's primary target indications — remain limited. Alnylam Pharmaceuticals has successfully commercialised inclisiran (Leqvio), a twice-yearly siRNA injection for high cholesterol, while Arrowhead has already demonstrated human ALK7 suppression in clinical trials with its ARO-ALK7 programme. Should competitors reach clinical readouts ahead of Olix in overlapping indications, Olix's negotiating leverage in future licensing deals could weaken. The return of rights for OLX301A — licensed to France's Théa Open Innovation in 2019 and handed back in June 2024 — also warrants careful scrutiny when assessing the durability of the company's partnerships.

Olix shares stood at 112,000 won as of 14 August, well below their 52-week high of 207,000 won. The stock trades at a projected 2026 price-to-book ratio of 10.2 times, down from 20.8 times in 2025, reflecting the capital raised in the recent rights offering. KIRS notes that the report is published for informational purposes and does not constitute a buy or sell recommendation.